Cancer Therapy with Chimeric Antigen Receptors - A Landmark Moment for Cancer Immunotherapy

Submit Manuscript | http://medcraveonline.com Abbreviations: ALL: Acute Lymphoblastic Lymphoma; BLA: Biologics License Application; CAR: Chimeric Antigen Receptor; CD19: Specific Antigen; CBER: Center for Biologics Evaluation and Research; CHOP: Children’s Hospital of Philadelphia; CLL: Chronic Lymphocytic Leukemia; CRS: Cytokine Release Syndrome; CTLA: Cytotoxic T-Lymphocyte Antigen; DNA: DeoxyriboNucleic Acid; ETASU: Elements To Assure Safe Use; FDA: (U.S.) Food & Drug Administration; FDCA: Food, Drug and Cosmetic Act; HGT: Human Gene Therapy; HCT: Human Cell Therapy; INDA: Investigational New Drug Application; MHC: Major Histocompatibility Complex; NCI: (U.S.) National Cancer Institute; PD: Programmed Death; REMS: Risk Evaluation and Mitigation Strategy; OCE: Oncology Center for Excellence; PHS: (U.S.) Public Health Service; PSHA: Public Health Service Act; REMA: Risk Evaluation and Mitigation Strategy; T-cell: a type of white blood cell (lymphocyte); TCR: T-Cell receptor; TIL: Tumor Infiltrating Lymphocyte.